BOSTON, Oct. 10, 2011 /PRNewswire/ -- PAREXEL Academy, a leading provider of education and professional training for the biopharmaceutical industry in the field of clinical research, which is operated by PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has entered into an agreement with the National University of Singapore (NUS), through its National University of Singapore Academy of GxP Excellence (NUSAGE), to offer an academic program in Singapore to help meet the increasing demand for talent in the field of clinical research in the Asia region. This demand is being driven by the growing complexity and globalization of biopharmaceutical research and development.
According to Dr. Albert Siu, Vice President, Learning and Development, PAREXEL International, "The Academy's location in Singapore provides students with access to a significant business center for the Asia/Pacific region, and supports regional growth in the clinical development field. These graduates will be empowered with the proper education to make a difference in the delivery of innovative new treatments to patients."
"We recognize NUS is among the world's leading universities with a globally-oriented focus and the ability to provide distinctive expertise and insights related to Asia. We expect our alliance with NUSAGE will deliver a world-class academic program focused on global best practices and the latest advances in the industry," said Dr. Siu.
"NUSAGE is pleased to partner with PAREXEL in this timely initiative to equip clinical development professionals with critical skills to effectively and efficiently translate research from the laboratory into clinical studies, and ultimately to bring significant life-saving treatments to patients in Asia and around the world," said Associate Professor Chan Sui Yung, Head of the Department of Pharmacy, NUS.
"For biomedical sciences companies looking to succeed in the rapidly-emerging Asian biopharmaceutical industry, Singapore offers a vantage point in Asia from which they can develop the requisite international and multidisciplinary talent to support their growth. The establishment of the first PAREXEL Academy in Asia, in Singapore, underscores the importance of developing talent in a diverse Asian clinical environment," said Mr. Kevin Lai, Deputy Director Biomedical Sciences, Singapore Economic Development Board.
Offering professional training and education since 2001, PAREXEL Academy, based in Berlin, Germany, provides postgraduate courses for clinical research associates, study nurses, and study coordinators. Training courses are also provided for investigators with special emphasis on conducting clinical trials in accordance with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) standards. For more information about PAREXEL Academy visit: http://www.PAREXEL-akademie.de/english/.
About National University of Singapore (NUS)A leading global university centred in Asia, the National University of Singapore (NUS) is Singapore's flagship university which offers a global approach to education and research, with a focus on Asian perspectives and expertise.
NUS has 16 faculties and schools across three campuses. Over 36,000 students from 100 countries enrich the community with their diverse social and cultural perspectives.
NUS has three Research Centres of Excellence (RCE) and 21 university-level research institutes and centres. It is also a partner in Singapore's 5th RCE. NUS shares a close affiliation with 16 national-level research institutes and centres. Research activities are strategic and robust, and NUS is well-known for its research strengths in engineering, life sciences and biomedicine, social sciences and natural sciences. It also strives to create a supportive and innovative environment to promote creative enterprise within its community.For more information, please visit www.nus.edu.sg
About NUSAGENUSAGE, established in March 2008, is the brainchild of the executives from the Economic Development Board of Singapore, the Pharmacy professors at the National University of Singapore and the senior executives of the pharmaceutical industry in Singapore and USA. NUSAGE has garnered strong support from major pharmaceutical and biological industry leaders as well as the government agencies in Singapore. It provides career entry and advancement pathways for PMETs (Professionals, Managers, Executives and Technicians) with degrees in health and basic sciences, engineering or relevant fields by equipping them with the specialized knowledge and advanced technical skills to join the strategic workforce to meet the evolving global regulatory standards. The "GxP excellence" mission of NUSAGE refers to establishing the best regulatory systems to ensure that medications, health products and services deliver safe, cost-effective, high quality and efficacious solutions to consumers everywhere. Visit http://www.nusage.nus.edu.sg for more information.
About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,550 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $18 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2011 as filed with the SEC on August 26, 2011, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations
Mr NG Swee Kang, Manager, Media RelationsPAREXEL International
National University of SingaporeTel: +781-434-4409
Tel: + 65-6516 5125Email: Jennifer.Baird@PAREXEL.com
|SOURCE PAREXEL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved